Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Inhibrx (INBX) stocks in Canada

Learn how to easily invest in Inhibrx stocks.

Inhibrx is a biotechnology business based in the US. Inhibrx stocks (INBX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $27.7 – a decrease of 10.4% over the previous week. Inhibrx employs 84 staff and has a trailing 12-month revenue of around $7.2 million.

How to buy shares in Inhibrx

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INBX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Inhibrx stock price (NASDAQ:INBX)

Use our graph to track the performance of INBX stocks over time.

Inhibrx shares at a glance

Information last updated 2022-01-17.
Latest market close$28.85
52-week range$14.27 - $47.90
50-day moving average $40.68
200-day moving average $30.77
Wall St. target price$54.20
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.07

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Inhibrx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Inhibrx price performance over time

Historical closes compared with the close of $28.85 from 2022-01-19

1 week (2022-01-13) -10.40%
1 month (2021-12-20) -32.78%
3 months (2021-10-20) -24.99%
6 months (2021-07-20) 2.23%
1 year (2021-01-20) -18.06%
2 years (2020-01-16) N/A
3 years (2019-01-16) N/A
5 years (2017-01-16) N/A

Inhibrx financials

Revenue TTM $7.2 million
Gross profit TTM $-60,607,000
Return on assets TTM -34.04%
Return on equity TTM -130.46%
Profit margin 0%
Book value $0.74
Market capitalisation $1.2 billion

TTM: trailing 12 months

Inhibrx share dividends

We're not expecting Inhibrx to pay a dividend over the next 12 months.

Inhibrx overview

Inhibrx, Inc. , a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.

Stocks similar to Inhibrx

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site